Melatonin as a pharmacotherapy option for recurrent CDI is theorized because of several potential anti-inflammatory mechanisms involving the inhibiting NLRP3 inflammasome activation, Toll-like receptor 4 (TLR4), and oxidative stress [20,21,22,23,24]. The gene discussed is TLR4; the disease is clostridium difficile infection.